SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Medi-Cal Expands Coverage Of Baseline HIV Resistance Testing
MGRM
|
|
|
Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that Medi-Cal has expanded its coverage of HIV resistance testing to include treatment naive patients as well as patients failing therapy. While genotypic resistance testing has traditionally been covered for patients who fail anti-HIV treatment, the expanded coverage allows for baseline genotypic resistance testing for all HIV infected patients, including those who are newly diagnosed and who are treatment naïve. Medi-Cal is California's Medicaid program, which provides medical service coverage for low-income and disabled individual< />< />< /><>< /><><>...
|
Monogram licenses patent portfolio to Caliper on an exclusive basis and Q1 Results..
MGRM
|
|
|
After the close this afternoon, Mongram BioSciences held a conference call to discuss the opportunity for Monogram's Trofile(TM) Assay in conjunction with Q1 results. Dr. Andrew Zolopa, a leading HIV physician from Stanford provided a compelling overview of Mongram's Trofile test and the current opportunities with Pfizer's new HIV drug Maravioc which recently received a unanimous recommendation from an FDA panel and pending approval.
Some e...
|
Monogram licenses patent portfolio to Caliper on an exclusive basis and Q1 Results..
MGRM
|
|
|
After the close this afternoon, Mongram BioSciences held a conference call to discuss the opportunity for Monogram's Trofile(TM) Assay in conjunction with Q1 results. Dr. Andrew Zolopa, a leading HIV physician from Stanford provided a compelling overview of Mongram's Trofile test and the current opportunities with Pfizer's new HIV drug Maravioc which recently received a unanimous recommendation from an FDA panel and pending approval.
Some e...
|
Monogram licenses patent portfolio to Caliper on an exclusive basis and Q1 Results..
MGRM
|
|
|
After the close this afternoon, Mongram BioSciences held a conference call to discuss the opportunity for Monogram's Trofile(TM) Assay in conjunction with Q1 results. Dr. Andrew Zolopa, a leading HIV physician from Stanford provided a compelling overview of Mongram's Trofile test and the current opportunities with Pfizer's new HIV drug Maravioc which recently received a unanimous recommendation from an FDA panel and pending approval.
Some e...
|
+10%
MGRM
|
|
|
With a +10% Institutional buying spree and enough money in the bank to milk another 6 months of "i think I can" from the laboratory its a great play.
|
From the Blogosphere
Monogram's Acquisition of LabCorp: What Does It Mean for the Molecular Diagnostics Industry?
By Grant Zeng, CFA Early yesterday morning, Laboratory Corporation of America® Holdings, or LabCorp (LH) and Monogram Biosciences, Inc. (MGRM) announced that they have entered into a definitive agreement and plan of merger under which LabCorp will acquire all of the outstanding shares of Monogram in a cash tender offer for $4.55 per share.
|
Unusual 11 Mid-Day Movers 6/23: MGRM, CGEN, GRH, RJET Higher; ACUR, HALO, PCBC, MTXX Lower
|
Monogram Biosciences, Inc. (NASDAQ: MGRM) <font>169% HIGHER;</font> Laboratory Corporation of America Holdings (NYSE: LH) and Monogram have entered into a definitive agreement and plan of merger under which LabCorp will acquire all of the outstanding shares of Monogram in a cash tender offer for $4.55 per share for an implied total equity value of approximately $106.7 million, or a total enterprise value of approximately $155 million at March 31, 2009, including net indebtedness.Compugen Ltd. (NASDAQ: CGEN) <font>45.5% HIGHER;</font> announced that CGEN-25007, a novel peptide antagonist of ...
|
Create Your Own Diagnostics ETF
|
|
|
With HealthShares closing shop at year-end, including the former Diagnostics fund, investors who are interested in the space can create their own ETF comprised of companies from the ETF Innovators Preventive Medicine and Emerging Diagnostics Indexes. Below is a list of companies which have stocks listed for trading in the U.S. at over $1/share with a market cap of less than $10B, focusing on smaller companies which are more leveraged to diagnostics and represent possible takeover targets for larger players such as Roche (RHHBY), Abbott Labs (ABT), and Johnson & Johnson (JNJ).
However, the sm...
|
Analyst initiations: MGRM, IPG and BCSI
Filed under: DaimlerChrysler (DAI), Analyst initiations  MOST NOTEWORTHY: Monogram Biosciences, Interpublic Group and Blue Coat Systems were today's noteworthy initiations:
<> JMP Securities said Monogram Biosciences (NASDAQ: MGRM) has a broad platform enabling it to develop multiple personalized medicine product offerings and has significant growth prospects from its HIV diagnostic business and its diagnostic test in oncology. Shares were initiated with an Outperform rating and $3.50 target.
<>Jefferies assumed Interpublic Group (NYSE: IPG) with a Buy rating and $11 target. The firm belie...
|
Monogram Must Manage Growth
MGRM
|
We would like to see how Monogram manages its top- and bottom-line growth before we recommend the shares.
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on MGRM |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Monogram Biosciences Inc.
- Answers.com
